With a strong background in medical statistics, Mubarak has dedicated his career to evaluating new treatments and shaping healthcare decisions in the UK. From 2019 to 2024, he worked at Warwick Evidence, where he provided statistical expertise for NICE appraisals, assessing the clinical and cost-effectiveness of new drugs. His work covered single and multiple technology appraisals, cancer drug funds, and diagnostic assessments, focusing on treatments for conditions such as multiple sclerosis, prostate and breast cancer, neovascular macular degeneration, and AI applications in medical imaging. He frequently collaborated with health economists, clinical experts, and NICE committees to inform NHS recommendations. He also attended appraisal committee meetings at NICE headquarters to defend the reports prepared by Warwick Evidence.
In 2025, Warwick Evidence merged with the Implementation Science and Surgical team at the University of Birmingham, forming the Birmingham Centre for Evidence and Implementation Science, where he continues his work. Alongside his research, he is pursuing a PhD by Published Works, focusing on ethnic differences in long-term cardiovascular health outcomes in the UK.
Before this, he worked at the Leicester Diabetes Centre as the lead statistician on multiple diabetes-related studies, conducting analyses for randomized controlled trials and observational studies. He contributed to study protocols, statistical analysis plans, and research publications.
Earlier, at the Macmillan Survivorship Research Group, he led statistical work on cancer survivorship studies, including the CREW study and the RCRT lung cancer study. He managed large datasets, prepared statistical analysis plans, and contributed to research publications.
With extensive experience in clinical research, pharmaceutical development, and statistical methodology, he continues to contribute to evidence-based healthcare improvements in the UK.